Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Newly-Published Colchicine Safety Data Provide First Evidence-Based Dosing Guidance to Avoid Potentially Serious Interactions With Commonly Prescribed Drugs

August 11, 2011 By Bio-Medicine.Org

PHILADELPHIA, Aug. 11, 2011 /PRNewswire/ — Newly-published
results from a series of colchicine safety studies provide
physicians with the first evidence-based dosing guidance for
colchicine when co-administered with certain commonly prescribed
drugs, helping doctors and patients avoid serious and potentially
life-threatening drug-drug interactions.

The study results, published in a paper titled “Evidence Basis
of a Novel Colchicine Dose Reduction Algorithm to Predict and
Prevent Colchicine Toxicity in the Presence of P-gp/CYP450 3A4
Inhibitors,” appear in the August issue of Arthritis &
Rheumatism,
the journal of the American College of
Rheumatology. The paper recommends colchicine dose reductions when
used with medications such as immunosuppressants, antibiotics,
hypertension drugs, anti-fungals and protease inhibitors.

The seven studies highlighted in the paper formed part of the
basis for URL Pharma’s New Drug Application (NDA) for Colcrys®
(colchicine, USP). Colcrys is the only single-ingredient colchicine
product to be reviewed and approved by the U.S. Food and Drug
Administration, and is indicated for the prophylaxis and treatment
of gout flares, and for the treatment of Familial Mediterranean
Fever (FMF).

The studies assessed cyclosporine, an immunosuppressant;
clarithromycin and azithromycin, two antibiotics; diltiazem and
verapamil, two hypertension drugs; ketoconazole, an anti-fungal
drug; and ritonavir, a protease inhibitor. Each of these drugs is
known to inhibit cytochrome P450 3A4 (CYP3A4) and/or P-glycoprotein
(P-gp).

Each of these drugs, except for azithromycin, was found to
interact significantly with standard colchicine dosing regimens, in
some cases more than doubling levels of colchicine in the blood and
increasing the risk of serious toxicities. Cyclosporine and
clarithromycin in particular increased peak colchicine blood levels
by nearly 300 percent. The authors recommended that colchicine
doses

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech